Osimertinib - AstraZeneca
Alternative Names: [11C]AZD9291; [11C]osimertinib; ADAURA; AZD-9291; Mereletinib; TAGRISSO; TagrissoLatest Information Update: 10 Jun 2025
At a glance
- Originator AstraZeneca
- Developer AstraZeneca; Avistone Pharmaceuticals; Dana-Farber Cancer Institute; Eli Lilly and Company; European Organisation for Research and Treatment of Cancer; European Thoracic Oncology Platform; G1 Therapeutics; Genprex; HUTCHMED; Incyte Corporation; Kyushu University; Molecular Partners AG; National Cancer Institute (USA); National University Hospital (Singapore); Princess Margaret Hospital (University of Toronto); Singapore Clinical Research Institute; Sunnybrook Health Sciences Centre; University of California at San Francisco
- Class Acrylamides; Amides; Aniline compounds; Antineoplastics; Dimethylamines; Indoles; Phenyl ethers; Pyrimidines; Small molecules
- Mechanism of Action Epidermal growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Non-small cell lung cancer
- Phase III Cancer; Meningeal carcinomatosis; Solid tumours
- Phase II Adenocarcinoma; Glioblastoma
Most Recent Events
- 02 Jun 2025 Efficacy and adverse event data from a phase III SACHI trial in Non-small cell lung cancer released by HUTCHMED
- 21 May 2025 Registered for Non-small cell lung cancer (Inoperable/Unresectable, Late-stage disease) in Canada (PO)
- 25 Mar 2025 Updated efficacy and adverse event data from a phase II ORCHARD trial in Non-small cell lung cancer released by AstraZeneca